AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7791015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical 0.5 mg PGE2 gel
Number of subjects: 467
Study 7791015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 3 mg PGE2 tablet
Number of subjects: 467
Study 3278823 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 10
Study 3278823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30916733 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-deactivation bag
Number of subjects: 0
Study 30916733 — intervention group
Group type: COMPARATOR
Intervention: Usual care or disposal information sheet
Number of subjects: 0
Study 29176768 — intervention group
Group type: EXPERIMENTAL
Intervention: Open administration of expressive writing intervention
Number of subjects: 0
Study 29176768 — intervention group
Group type: COMPARATOR
Intervention: Hidden administration of expressive writing intervention
Number of subjects: 0
Study 25961456 — intervention group
Group type: EXPERIMENTAL
Intervention: Notch signaling activation
Number of subjects: 0
Study 25961456 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of Notch signaling (genetic or pharmacological approaches)
Number of subjects: 0
Study 25961456 — intervention group
Group type: COMPARATOR
Intervention: Notch pathway activity (elevated)
Number of subjects: 0
Study 23514584 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus monotherapy (25 mg weekly)
Number of subjects: 64
Study 23514584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (irinotecan 180 mg/m2 biweekly + temsirolimus)
Number of subjects: 64
Study 18193579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortexin
Number of subjects: 80
Study 18193579 — intervention group
Group type: COMPARATOR
Intervention: Nootropil
Number of subjects: 80
Study 18193579 — intervention group
Group type: COMPARATOR
Intervention: Cerebrolysin
Number of subjects: 80
Study 14566709 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery intervention (audiotaped)
Number of subjects: 62
Study 10569465 — intervention group
Group type: EXPERIMENTAL
Intervention: Office dust exposure (439 microg/m3)
Number of subjects: 23
Study 10569465 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure (17 microg/m3)
Number of subjects: 23
Study 10569465 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial provocation with histamine
Number of subjects: 23
Study 10569465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mucosal swelling
Number of subjects: 23
Study 10569465 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye irritation tests (threshold for eye irritation with carbon dioxide, eye redness, cellular content of conjunctival fluid)
Number of subjects: 23
Study 8915019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl loaded ethylene vinyl acetate co‐polymer fiber placed into the periodontal pocket of 1 randomly selected tooth
Number of subjects: 35
Study 8915019 — intervention group
Group type: COMPARATOR
Intervention: No further treatment on a non-adjacent tooth with persistent or recurrent periodontitis
Number of subjects: 35
Study 1856141 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg/day given as a single dose
Number of subjects: 220
Study 1856141 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg/day given in two divided doses at 12‐h intervals
Number of subjects: 220
Study 6349646 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium, 200 mg/day
Number of subjects: 757
Study 6349646 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium, 300 mg/day
Number of subjects: 757
Study 6349646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 757
Study 6349646 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA), 3.6 g/day
Number of subjects: 757
Study 29947474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg orally disintegrating film
Number of subjects: 47
Study 29947474 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg film-coated tablets (Viagra®, Pfizer, Mexico)
Number of subjects: 47
Study 29947474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 47
Study 28438118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowenstein-Jensen (LJ) culture method
Number of subjects: 100
Study 28438118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacteria growth indicator tube (MGIT) culture method
Number of subjects: 100
Study 28438118 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin-based regimens (R10, 15 and 20 mg/Kg)
Number of subjects: 100
Study 26412308 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) alone
Number of subjects: 260
Study 26412308 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate (GTN) alone
Number of subjects: 260
Study 26412308 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) + Glyceryl Trinitrate (GTN)
Number of subjects: 260
Study 26412308 — intervention group
Group type: COMPARATOR
Intervention: Neither RIC nor GTN (sham RIC)
Number of subjects: 260
Study 24050454 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning every 2 hours
Number of subjects: 942
Study 24050454 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning every 3 hours
Number of subjects: 942
Study 24050454 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning every 4 hours
Number of subjects: 942
Study 24050454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk participants (repositioning schedule)
Number of subjects: 942
Study 24050454 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-risk participants (repositioning schedule)
Number of subjects: 942
Study 24050454 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of repositioning groups
Number of subjects: 942
Study 24050454 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of risk groups
Number of subjects: 942
Study 22319956 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-verbalization group (n=18)
Number of subjects: 56
Study 22319956 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter-verbalization group (n=21)
Number of subjects: 56
Study 22319956 — intervention group
Group type: COMPARATOR
Intervention: Non-verbalization control group (n=17)
Number of subjects: 56
Study 19247202 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN induction therapy (27 or 18 mg q.d.)
Number of subjects: 217
Study 17084191 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic motor‐evoked potentials (tcMMEPs)
Number of subjects: 20
Study 17084191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatomal somatosensory‐evoked potentials (d‐SSEPs)
Number of subjects: 20
Study 15337003 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography for detection of ARM
Number of subjects: 120
Study 15337003 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography for morphology evaluation
Number of subjects: 120
Study 15337003 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative detection of ARM
Number of subjects: 120
Study 11577792 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation therapy
Number of subjects: 0
Study 11577792 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy or chemoradiation
Number of subjects: 0
Study 11577792 — intervention group
Group type: EXPERIMENTAL
Intervention: Various chemotherapy regimens
Number of subjects: 0
Study 9205931 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day and/or hydrochlorothiazide 12.5-25 mg/day)
Number of subjects: 3433
Study 9205931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3433
Study 8035470 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic self-disclosure in couples during 10 weekly sessions
Number of subjects: 20
Study 3663958 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cancers detected clinically in women under 50 years old
Number of subjects: 60
Study 3663958 — intervention group
Group type: EXPERIMENTAL
Intervention: True interval tumours (31 out of 60)
Number of subjects: 60
Study 3663958 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-true interval tumours (29 out of 60)
Number of subjects: 60
Study 3663958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of interval cancers
Number of subjects: 60
Study 3663958 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening the screening interval
Number of subjects: 60
Study 29957868 — intervention group
Group type: EXPERIMENTAL
Intervention: Camicinal 50 mg daily for a maximum of 7 days
Number of subjects: 84
Study 29957868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 28219403 — intervention group
Group type: EXPERIMENTAL
Intervention: Full KiVa program group
Number of subjects: 1495
Study 28219403 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial KiVa (without online game) program group
Number of subjects: 1495
Study 28219403 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1495
Study 25643020 — intervention group
Group type: EXPERIMENTAL
Intervention: LF milk-based formula
Number of subjects: 296
Study 25643020 — intervention group
Group type: EXPERIMENTAL
Intervention: LF soy-based formula
Number of subjects: 296
Study 25643020 — intervention group
Group type: COMPARATOR
Intervention: Milk-based, lactose-containing formula
Number of subjects: 296
Study 23721984 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 0
Study 23721984 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure education program (sodium restriction and walking program)
Number of subjects: 0
Study 23721984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination program (yoga therapy and lifestyle modification)
Number of subjects: 0
Study 21108619 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐CPAP at 10 cmH₂O
Number of subjects: 14
Study 21108619 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐CPAP at 10 cmH₂O
Number of subjects: 14
Study 21108619 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐CPAP at 10 cmH₂O
Number of subjects: 14
Study 21108619 — intervention group
Group type: COMPARATOR
Intervention: E‐CPAP vs HF‐CPAP and V‐CPAP
Number of subjects: 14
Study 18362654 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mitomycin C (MMC) 0.2 mg/mL
Number of subjects: 52
Study 18362654 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (Control)
Number of subjects: 52
Study 17044575 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care BNP measurement
Number of subjects: 88
Study 12760984 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 10 mg/kg orally (Control)
Number of subjects: 120
Study 12760984 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 10 mg/kg with 1 mg/kg of codeine orally
Number of subjects: 120
Study 12760984 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 25 micro g/kg given immediately after the induction of anesthesia
Number of subjects: 120
Study 12760984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg/kg given IM immediately after the induction of anesthesia
Number of subjects: 120
Study 10768327 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective zonal ablation with excimer laser
Number of subjects: 26
Study 10768327 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 26
Study 8933184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OTB) 600 micrograms/day
Number of subjects: 24
Study 8933184 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study 1425888 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS) 30 cm2
Number of subjects: 12
Study 1425888 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 12
Study 1425888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6377487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute excision of all burned areas (superficial dermal plus deep dermal plus subdermal burns) and grafted as quickly as possible after the accident (group A, 73 patients)
Number of subjects: 149
Study 6377487 — intervention group
Group type: COMPARATOR
Intervention: Exposure treatment until day 14 post-burn, followed by excision and grafting of non-spontaneously healed areas (group E, 76 patients)
Number of subjects: 149
Study 31256105 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-height table
Number of subjects: 20
Study 31256105 — intervention group
Group type: COMPARATOR
Intervention: Sofa
Number of subjects: 20
Study 31256105 — intervention group
Group type: COMPARATOR
Intervention: Bed
Number of subjects: 20
Study 29806282 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 56
Study 29806282 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 56
Study 26775249 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 2819
Study 26775249 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 2819
Study 24852569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral UDCA treatment (ursodeoxycholic acid) after esophageal perfusion with DCA (250 μM) for 8 weeks
Number of subjects: 21
Study 24852569 — intervention group
Group type: COMPARATOR
Intervention: DCA perfusion (250 μM)
Number of subjects: 21
Study 24852569 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour pretreatment with UDCA
Number of subjects: 21
Study 24852569 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA treatment
Number of subjects: 21
Study 21856760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized LDL (oxLDL) in immune complexes (IC)
Number of subjects: 302
Study 21856760 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced glycation end‐product (AGE)‐LDL in immune complexes (IC)
Number of subjects: 302
Study 19680238 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the portion size of fruit side dish (applesauce)
Number of subjects: 43
Study 19680238 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the portion size of vegetable side dishes (broccoli, carrots)
Number of subjects: 43
Study 19680238 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the portion size of F&V side dishes
Number of subjects: 43
Study 17434106 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose 125I seeds (LS)
Number of subjects: 64
Study 17434106 — intervention group
Group type: COMPARATOR
Intervention: Stranded 125I seeds (RS)
Number of subjects: 64
Study 15807285 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide (1.0 mg tid)
Number of subjects: 46
Study 15807285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (90.0 mg tid)
Number of subjects: 46
Study 15807285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Repaglinide and Nateglinide)
Number of subjects: 46
Study 12040357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg of WS 1442
Number of subjects: 209
Study 12040357 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of WS 1442
Number of subjects: 209
Study 12040357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 9888474 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg anastrozole
Number of subjects: 34
Study 9888474 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 34
Study 9888474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamoxifen and anastrozole
Number of subjects: 34
Study 8646294 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberate (ion-exchange chromatography purified factor VIII concentrate)
Number of subjects: 15
Study 8646294 — intervention group
Group type: COMPARATOR
Intervention: Z8 (intermediate-purity concentrate, terminally heated at 80 degrees C for 72 h)
Number of subjects: 15
Study 8646294 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberate and Z8
Number of subjects: 15
Study 2105563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 4
Study 2105563 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 4
Study 497090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin tablets
Number of subjects: 0
Study 497090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin capsules
Number of subjects: 0
Study 497090 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin capsules and tablets
Number of subjects: 0
Study 29668860 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice daily
Number of subjects: 107
Study 29668860 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, both every 3 weeks)
Number of subjects: 107
Study 29668860 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 107
Study 29668860 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 107
Study 27696275 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy Arousal
Number of subjects: 341
Study 27696275 — intervention group
Group type: EXPERIMENTAL
Intervention: Condemning Behavior
Number of subjects: 341
Study 27696275 — intervention group
Group type: COMPARATOR
Intervention: Blaming the Bully
Number of subjects: 341
Study 25918184 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cardiometabolic disorders (MetS) at midlife
Number of subjects: 2788
Study 25918184 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-unit increase in the number of cardiometabolic disorders
Number of subjects: 2788
Study 25918184 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific cardiometabolic disorders (hyperglycaemia, central obesity, dyslipidaemia)
Number of subjects: 2788
Study 23057761 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention for malnourished patients
Number of subjects: 162
Study 23057761 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-malnourished patients)
Number of subjects: 162
Study 20471003 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min night‐nap
Number of subjects: 24
Study 20471003 — intervention group
Group type: COMPARATOR
Intervention: No night‐nap
Number of subjects: 24
Study 18405147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 72
Study 18405147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and medication
Number of subjects: 72
Study 18405147 — intervention group
Group type: COMPARATOR
Intervention: Medication (Methyl vitamin B12 250 microg, once daily)
Number of subjects: 72
Study 16802194 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Eliminator group
Number of subjects: 287
Study 16802194 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Reducer group
Number of subjects: 287
Study 16802194 — intervention group
Group type: EXPERIMENTAL
Intervention: High Risk group
Number of subjects: 287
Study 11885342 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free instant hand sanitizer
Number of subjects: 769
Study 11885342 — intervention group
Group type: COMPARATOR
Intervention: Placebo hand sanitizer
Number of subjects: 769
Study 9680558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol of gadopentetate dimeglumine per kilogram of body weight
Number of subjects: 34
Study 9680558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol of gadopentetate dimeglumine per kilogram of body weight
Number of subjects: 34
Study 9680558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol of gadopentetate dimeglumine per kilogram of body weight
Number of subjects: 34
Study 7731420 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol breath hydrogen test
Number of subjects: 40
Study 2686956 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclobrate (100 mg)
Number of subjects: 20
Study 2686956 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate (400 mg)
Number of subjects: 20
Study 8204997 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg per day
Number of subjects: 0
Study 8204997 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 150 mg per day
Number of subjects: 0
Study 497671 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet
Number of subjects: 11
Study 497671 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 11
Study 31907004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological conditioning group (PC) receiving MTX in alternating high and low dosages
Number of subjects: 0
Study 31907004 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) continuing with standardized treatment schedule of MTX 15 mg/week
Number of subjects: 0
Study 31907004 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes include clinical functioning, laboratory assessments, and self-reported measures
Number of subjects: 0
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: Major therapeutic changes (MTC)
Number of subjects: 941
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening DAS28 at index
Number of subjects: 941
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28 improvements
Number of subjects: 941
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: No change in DAS28
Number of subjects: 941
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: No MTC in worsening DAS28
Number of subjects: 941
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: No MTC in no change in DAS28
Number of subjects: 941
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: No MTC in improved DAS28
Number of subjects: 941
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroid or nbDMARD use
Number of subjects: 941
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of nbDMARDs in previous 90 days
Number of subjects: 941
Study 30418115 — intervention group
Group type: EXPERIMENTAL
Intervention: Reason for not modifying therapy
Number of subjects: 941
Study 28431766 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 717